Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will participate in the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 in New York City.
The conference will feature more than 60 selected companies, over 500 institutional and high-net-worth investors, main-stage presentations, expert panels, curated one-on-one meetings, and networking sessions designed to connect growth companies with the investment community.
Investors seeking registration or agenda details are directed to the Spartan Capital Investor Conference 2025 registration page.
Positive
- None.
Negative
- None.
News Market Reaction – RVPH
In the Oct 29 session, RVPH gained 1.68%, reflecting a mild positive market reaction. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, in New York City.
The conference will showcase more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors. Over 500 institutional and high-net-worth investors are expected to attend. The event will feature main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions, creating meaningful opportunities for dialogue between growth companies and the investment community.
For more information about the conference and registration details, please visit Spartan Capital Investor Conference 2025 Registration.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
